SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steven Osborne who wrote (623)9/18/1999 8:51:00 PM
From: Joe Bilich  Read Replies (1) of 1298
 
fwiw--the Bank Boston Robertson Stevens analyst reviewed CEGE after the announcement of the pullout by Hoescht. The analyst summarized it as a positive development and projected that CEGE would be successful in finding another partner for this work over the next 12 months.

IR at CEGE characterized the development as positive as well, and indicated that, although nothing was just around the corner, they had received some inquiries from other parties about participating in this research even prior to the Hoescht pullout.

Both noted that the Hoescht decision may be linked to more Hoescht's status (they are right in the middle of a merger, and probably rationalizing the research portfolio top to bottom) than to the quality of CEGE's science.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News